.jpg "Diplomat Pharmacy (NYSE: DPLO)")
Today, a Director at Diplomat Pharmacy (NYSE: DPLO), Kenneth Klepper, sold shares of DPLO for $40.76K.
In addition to Kenneth Klepper, 2 other DPLO executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Diplomat Pharmacy’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $1.34 billion and GAAP net loss of $450K. In comparison, last year the company earned revenue of $1.08 billion and had a net profit of $4.37 million. DPLO’s market cap is $1.8B and the company has a P/E ratio of 173.5. Currently, Diplomat Pharmacy has an average volume of 578.2K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $27.33, reflecting a -9.3% downside.
The insider sentiment on Diplomat Pharmacy has been negative according to 18 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Diplomat Pharmacy, Inc. engages in the provision of pharmacy services. It focuses on improving the lives of patients with complex chronic diseases while delivering solutions for manufacturers, hospitals, payers, and providers.The company was founded by Dale Hagerman and Philip Hagerman in 1975 and is headquartered in Flint, MI.
